Cost-utility analysis of olaparib assisted targeted therapy for BRCA mutation HER2-negative early breast cancer in China and in the United States
When evaluated in the context of healthcare economics in both China and the United States, the implementation of an Olaparib-based treatment strategy for early-stage HER2-negative breast cancer with BRCA mutations does not present a cost-effective solution in either nation.
Authors
- Jiaqin Cai (ORCID: https://orcid.org/0000-0002-8223-3187)
- Jie Zhuang (ORCID: https://orcid.org/0000-0002-5472-9118)
- Hong Sun (ORCID: https://orcid.org/0000-0002-0445-8954)
- Chenxia Xu
- Jeannie Shen (ORCID: https://orcid.org/0000-0001-9193-8827)
- Xiaoxia Wei (ORCID: https://orcid.org/0000-0002-7350-3464)
Institutions
- Fujian Medical University (CN)
- Fujian Provincial Hospital (CN)
- Union Hospital (CN)
Publication Details
- Journal
- Cost Effectiveness and Resource Allocation
- Published
- 2025-04-13
- DOI
- https://doi.org/10.1186/s12962-025-00617-9
- Citations
- 3
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 3.14
Funders
- Fujian Provincial Health Technology Project